Virbac confirms 2026 outlook while Virbac stock sits 20.41 percent below its high

Published on 10/05/2026 at 16:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac reported EUR 768 million revenue, up 7.40 percent in the first half of 2026. Virbac stock costs EUR 310.00 on October 5, 2026 versus EUR 309.25.

3D-Architekturvisualisierung eines modernen Forschungsgebäudes für Tiergesundheit — Architektonisches 3D-Render veranschaulicht die künftige Firmenzentrale von Virbac S.A., ISIN FR0000031577, moderne Pharma-Forschungsanlage Frankreich, Illustration mit AI erstellt.

Virbac confirmed its 2026 outlook at the upper end of the 5.50 percent to 7.50 percent revenue-growth range on September 17, 2026, as first-half revenue reached EUR 768.0 million, according to Virbac. Virbac stock was EUR 310.00 at Lang & Schwarz on October 5, 2026, placing it 20.41 percent below its 52-week high of EUR 389.50. The combination gives investors a clear split between stronger operating momentum and a share price still below its yearly peak.

First-half growth supports guidance

The first half delivered revenue growth of 7.40 percent at constant exchange rates and scope, while adjusted EBIT reached EUR 144.2 million versus EUR 135.0 million in the first half of 2025. That comparison represents growth of 6.80 percent and supports the company's decision to target the upper end of its full-year revenue range.

Adjusted EBIT margin rose to 18.80 percent from 18.30 percent, an increase of 0.50 percentage points. Consolidated net income reached EUR 87.1 million, up 5.90 percent from the first half of 2025, according to Reuters on September 17, 2026.

Animal health platforms drive the mix

Virbac said companion-animal revenue grew 10.00 percent in the first half, while farm-animal revenue increased 6.70 percent. Its Supercharge platforms grew 12.00 percent excluding Thyronorm, and the acquisition added 3.70 percentage points to platform growth.

The product mix matters because Virbac is combining volume and pricing with specialty products. The company reported a volume and mix contribution of 5.40 percent and price increases of 2.00 percent, while net debt reached EUR 196 million at June 2026 versus EUR 173 million at December 2025.

Stock stays below its yearly high

Virbac's market capitalization was EUR 2.6 billion on October 5, 2026, and its 52-week range was EUR 297.00 to EUR 389.50. The Lang & Schwarz price of EUR 310.00 stood EUR 0.75 above the prior close of EUR 309.25, a daily change of plus 0.24 percent.

The further course of trading is shown by the continuously updated real-time quote of Virbac stock.